Follicular Lymphoma Overview

Follicular lymphoma (FL) is typically a slow-growing or indolent form of non- Hodgkin lymphoma (NHL) that arises from Blymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 to 30 percent of all NHL cases. Follicular lymphoma is usually not considered to be curable, but more of a chronic disease. Patients can live for many years with this form of lymphoma. Follicular lymphoma is a B-cell lymphoma. It is characterized by the transformation of a B-cell into a malignant (cancerous) cell.

“Follicular Lymphoma Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market. 

The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Follicular Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years. Follicular Lymphoma Key players such as – InnoCare Pharma, Sound Biologics, Merck KGaA, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, MEI Pharma, Dr Reddy’s Laboratories, Pharmacyclics, and others, are developing therapies for the Follicular Lymphoma treatment 

• Follicular Lymphoma Emerging therapies such as – ICP 248, PSB 202, Avelumab, Abexinostat, Loncastuximab tesirine, Acalabrutinib, Zandelisib, DRL_RI, Ibrutinib, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.   
• In August 2021, MEI Pharma, Inc. initiated a trial titled ” A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemo therapy in Patients With Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) – The COASTAL Study”
• In November 2021, MEI Pharma, Inc. and Kyowa Kirin, announced that the U.S. Food and Drug Administration(FDA) granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma 

Follicular Lymphoma Pipeline Therapeutics Assessment

• Follicular Lymphoma Assessment by Product Type
• Follicular Lymphoma By Stage and Product Type
• Follicular Lymphoma Assessment by Route of Administration
• Follicular Lymphoma By Stage and Route of Administration
• Follicular Lymphoma Assessment by Molecule Type
• Follicular Lymphoma by Stage and Molecule Type 

DelveInsight’s Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include: 

• ICP 248: InnoCare Pharma
• PSB 202: Sound Biologics
• Avelumab: Merck KGaA
• Abexinostat: Xynomic Pharmaceuticals
• Loncastuximab tesirine: ADC Therapeutics
• Acalabrutinib: AstraZeneca
• Zandelisib: MEI Pharma
• DRL_RI: Dr Reddy’s Laboratories
• Ibrutinib: Pharmacyclics 

Follicular Lymphoma Pipeline Analysis:

The Follicular Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Follicular Lymphoma treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
• Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies

Follicular Lymphoma Pipeline Market Drivers

• Increase in prevalence of Follicular Lymphoma
• Emergence of effective novel therapies

Follicular Lymphoma Pipeline Market Barriers

• Lack Of Cost-Effective Treatment

Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Assessment

Scope of Follicular Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key Follicular Lymphoma Companies: InnoCare Pharma, Sound Biologics, Merck KGaA, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, MEI Pharma, Dr Reddy’s Laboratories, Pharmacyclics, and others
• Key Follicular Lymphoma Therapies: ICP 248, PSB 202, Avelumab, Abexinostat, Loncastuximab tesirine, Acalabrutinib, Zandelisib, DRL_RI, Ibrutinib, and others
• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
• Follicular Lymphoma Market Dynamics:  Follicular Lymphoma market drivers and Follicular Lymphoma market barriers 

Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com